Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.6.5 to v3.6.6, indicating a minor platform update rather than a change to the study details.
    Difference
    0.1%
    Check dated 2026-08-30T16:38:03.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    37 days ago
    Change Detected
    Summary
    The page footer now displays Revision: v3.6.5 instead of v3.6.4, indicating an internal site update without changing the trial details.
    Difference
    0.1%
    Check dated 2026-08-09T10:56:12.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    A new site revision label (v3.6.4) was added, signaling a deployment update to the platform rather than a change to the study information.
    Difference
    0.1%
    Check dated 2026-07-25T18:26:43.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    Footer revision updated to Revision: v3.6.3 replacing the previous Revision: v3.6.2. This indicates a deployment/version bump with no changes to study details.
    Difference
    0.1%
    Check dated 2026-07-04T08:25:32.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    The footer revision was updated from v3.6.0 to v3.6.2, indicating a minor build update. No content or functionality changes are introduced on the study details page.
    Difference
    0.1%
    Check dated 2026-06-27T07:00:54.000Z thumbnail image
  9. Check
    94 days ago
    Change Detected
    Summary
    The page adds new navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label; the revision tag changes from v3.5.5 to v3.6.0, and an investigator credit for Prof. dr. E.F. Smit is added while the combined investigator line is removed.
    Difference
    2%
    Check dated 2026-06-13T05:20:44.000Z thumbnail image

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.